Use of nanoparticles for drug delivery in glioblastoma multiforme.
Use of nanoparticles for drug delivery in glioblastoma multiforme.
复制标题
DOI：
10.1586/14737175.7.4.363
复制
发表时间：
2007-04-01
影响因子：
4.3
通讯作者：
Jain, K K
中科院分区：
文献类型：
--
作者：
Jain, K K
多形性胶质母细胞瘤（GBM）是一种原发性脑恶性肿瘤，其治疗是最具挑战性的问题之一，因为目前尚无可治愈的治疗方法。手术仍然是基本的治疗方法，切除大部分肿瘤，外围浸润部分是补充治疗的目标。目前可用的抗癌治疗方法对GBM的疗效不理想，主要是由于肿瘤的输送问题，包括血脑屏障。除了目前直接将药物和设备引入肿瘤的做法外，正在开发的几种GBM新疗法将需要创新的给药方法。纳米生物技术，特别是纳米颗粒，正在为改善癌症的药物输送做出重大贡献，其中许多技术可以应用于GBM。纳米生物技术可以为诊断、治疗和将其输送到肿瘤并随后监测反应提供一个结合的平台。对这些技术进行了回顾，并认为在未来5年内，改善脑部治疗的前景是非常好的。然而，GBM的治愈取决于一种能够完全摧毁GBM的抗癌剂的发现。
Treatment of glioblastoma multiforme (GBM), a primary malignant tumor of the brain, is one of the most challenging problems as no currently available treatment is curative. Surgery remains the basic treatment in which the bulk of the tumor is removed and the peripheral infiltrating part is the target of supplementary treatments. The currently available anticancer therapeutics have less than optimal usefulness for GBM, mainly owing to delivery problems to the tumor, including those due to blood-brain barrier. Several new therapies in development for GBM will require innovative methods of delivery besides the current practice of direct introduction of drugs and devices into the tumor. Nanobiotechnology, particularly nanoparticles, is making a significant contribution to the improvement of drug delivery in cancer and many of these technologies can be applied to GBM. Nanobiotechnology can provide a platform for combination of diagnostics, therapeutics, and its delivery to the tumor with subsequent monitoring of response. These technologies are reviewed and the prospects of improvement of therapeutic delivery to the brain are excellent during the next 5 years. Curing of GBM, however, depends on discovery of an anticancer agent that will destroy GBM completely.